CN110950949B - 一种识别ssx2抗原的t细胞受体 - Google Patents

一种识别ssx2抗原的t细胞受体 Download PDF

Info

Publication number
CN110950949B
CN110950949B CN201811123747.0A CN201811123747A CN110950949B CN 110950949 B CN110950949 B CN 110950949B CN 201811123747 A CN201811123747 A CN 201811123747A CN 110950949 B CN110950949 B CN 110950949B
Authority
CN
China
Prior art keywords
tcr
amino acid
seq
chain
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811123747.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110950949A (zh
Inventor
李懿
胡静
李俊
孙含丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiangxue Life Science Technology Guangdong Co ltd
Original Assignee
Xiangxue Life Science Technology Guangdong Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiangxue Life Science Technology Guangdong Co ltd filed Critical Xiangxue Life Science Technology Guangdong Co ltd
Priority to CN201811123747.0A priority Critical patent/CN110950949B/zh
Priority to PCT/CN2019/107097 priority patent/WO2020063488A1/zh
Priority to US17/279,372 priority patent/US11649270B2/en
Priority to JP2021517352A priority patent/JP7452880B2/ja
Priority to CA3114451A priority patent/CA3114451A1/en
Priority to EP19864082.3A priority patent/EP3858852B1/en
Publication of CN110950949A publication Critical patent/CN110950949A/zh
Application granted granted Critical
Publication of CN110950949B publication Critical patent/CN110950949B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201811123747.0A 2018-09-26 2018-09-26 一种识别ssx2抗原的t细胞受体 Active CN110950949B (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN201811123747.0A CN110950949B (zh) 2018-09-26 2018-09-26 一种识别ssx2抗原的t细胞受体
PCT/CN2019/107097 WO2020063488A1 (zh) 2018-09-26 2019-09-20 一种识别ssx2抗原的t细胞受体
US17/279,372 US11649270B2 (en) 2018-09-26 2019-09-20 T-cell receptor recognizing SSX2 antigen
JP2021517352A JP7452880B2 (ja) 2018-09-26 2019-09-20 Ｓｓｘ２抗原を識別するｔ細胞受容体
CA3114451A CA3114451A1 (en) 2018-09-26 2019-09-20 T cell receptor for identifying ssx2 antigen
EP19864082.3A EP3858852B1 (en) 2018-09-26 2019-09-20 T-cell receptor recognizing ssx2 antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811123747.0A CN110950949B (zh) 2018-09-26 2018-09-26 一种识别ssx2抗原的t细胞受体

Publications (2)

Publication Number Publication Date
CN110950949A CN110950949A (zh) 2020-04-03
CN110950949B true CN110950949B (zh) 2022-04-05

Family

ID=69949278

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811123747.0A Active CN110950949B (zh) 2018-09-26 2018-09-26 一种识别ssx2抗原的t细胞受体

Country Status (6)

Country Link
US (1) US11649270B2 (https=)
EP (1) EP3858852B1 (https=)
JP (1) JP7452880B2 (https=)
CN (1) CN110950949B (https=)
CA (1) CA3114451A1 (https=)
WO (1) WO2020063488A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力t细胞受体
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN114524870A (zh) * 2020-11-23 2022-05-24 香雪生命科学技术（广东）有限公司 源自于ssx2抗原的短肽
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
KR20250028371A (ko) 2022-07-01 2025-02-28 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
CN121620513A (zh) 2023-07-26 2026-03-06 吉利德科学公司 Parp7抑制剂
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
AU2003270311A1 (en) * 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
NZ564359A (en) 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
CN103124740B (zh) 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
CN102173056B (zh) * 2010-12-30 2014-09-03 联塑(杭州)机械有限公司 形成发泡产品的方法及其系统
AU2014301777B2 (en) 2013-06-26 2017-03-30 Xlifesc, Ltd. High-stability T-cell receptor and preparation method and application thereof
GB201313377D0 (en) 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
JP6777841B2 (ja) * 2015-10-23 2020-10-28 国立大学法人金沢大学 細胞傷害性ｔ細胞の作製方法
CN106519019B (zh) * 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
CN108117596B (zh) * 2016-11-29 2023-08-29 香雪生命科学技术（广东）有限公司 针对ny-eso的高亲和力tcr
EP3731876A4 (en) * 2017-12-28 2022-04-06 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS
CN110343167B (zh) * 2018-04-03 2022-10-28 香雪生命科学技术（广东）有限公司 识别ssx2抗原短肽的t细胞受体
MX2021011462A (es) * 2019-03-25 2021-12-15 Univ Health Network Receptores de linfocitos t y metodos de uso de los mismos.

Also Published As

Publication number Publication date
EP3858852B1 (en) 2023-06-21
US20210395330A1 (en) 2021-12-23
JP2022502056A (ja) 2022-01-11
CA3114451A1 (en) 2020-04-02
JP7452880B2 (ja) 2024-03-19
EP3858852C0 (en) 2023-06-21
US11649270B2 (en) 2023-05-16
EP3858852A1 (en) 2021-08-04
WO2020063488A1 (zh) 2020-04-02
EP3858852A4 (en) 2022-06-15
CN110950949A (zh) 2020-04-03

Similar Documents

Publication Publication Date Title
CN110950949B (zh) 一种识别ssx2抗原的t细胞受体
CN106632660B (zh) 识别ny-eso-1抗原短肽的tcr
CN107197625B (zh) 识别ny-eso-1抗原短肽的t细胞受体
CN112646024A (zh) 一种识别kras突变的t细胞受体及其编码序列
CN110776562B (zh) 一种识别afp抗原的t细胞受体
CN106831978B (zh) 识别prame抗原的t细胞受体
CN110343166B (zh) 识别afp抗原短肽的t细胞受体
CN110343167B (zh) 识别ssx2抗原短肽的t细胞受体
CN109575121B (zh) 识别afp抗原短肽的t细胞受体
CN110577591B (zh) 一种识别afp抗原短肽的t细胞受体及其编码序列
CN113321726A (zh) 一种识别hpv的t细胞受体
CN106336457B (zh) 识别mage‑a3抗原短肽的t细胞受体
CN113321727B (zh) 一种识别afp抗原短肽的t细胞受体及其编码序列
CN108264550B (zh) 一种识别源自于prame抗原短肽的tcr
CN113072635A (zh) 一种识别hpv抗原的t细胞受体及其编码序列
JP2022549994A (ja) Ｓｓｘ２抗原の短いペプチドを識別するｔ細胞受容体
CN109251243B (zh) 一种识别sage1抗原的t细胞受体及编码该受体的核酸
CN113072636B (zh) 一种识别afp的t细胞受体及其编码序列
CN110407927B (zh) 一种识别afp抗原的tcr
CN109400696B (zh) 一种识别prame抗原短肽的tcr
CN109400697B (zh) 一种识别prame抗原短肽的tcr及其相关组合物
CN108948184B (zh) 一种识别衍生自prame抗原短肽的t细胞受体
CN113321725A (zh) 一种识别afp的t细胞受体
CN110577590B (zh) 一种识别afp抗原的tcr及其编码核酸
CN109575120B (zh) 识别prame抗原短肽的tcr及其编码序列

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210412

Address after: 519031 2715 office building, no.3000 Huandao East Road, Hengqin New District, Zhuhai City, Guangdong Province

Applicant after: Xiangxue Life Science Technology (Guangdong) Co.,Ltd.

Address before: 510663 No.2, jinfengyuan Road, Science City, Guangzhou hi tech Industrial Development Zone, Guangdong Province

Applicant before: GUANGDONG XIANGXUE LIFE SCIENCES, Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
PP01 Preservation of patent right

Effective date of registration: 20250507

Granted publication date: 20220405

PP01 Preservation of patent right
PD01 Discharge of preservation of patent

Date of cancellation: 20251104

Granted publication date: 20220405

PD01 Discharge of preservation of patent
PP01 Preservation of patent right

Effective date of registration: 20260309

Granted publication date: 20220405

PP01 Preservation of patent right